These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9489130)

  • 21. Determination of activated lymphocytes in peripheral blood of patients with multiple sclerosis.
    Crockard AD; McNeill TA; McKirgan J; Hawkins SA
    J Neurol Neurosurg Psychiatry; 1988 Jan; 51(1):139-41. PubMed ID: 2965217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of the biology of type I interferons.
    Kalliolias GD; Ivashkiv LB
    Arthritis Res Ther; 2010; 12 Suppl 1(Suppl 1):S1. PubMed ID: 20392288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virus-induced interferon alpha/beta (IFN-alpha/beta) production by T cells and by Th1 and Th2 helper T cell clones: a study of the immunoregulatory actions of IFN-gamma versus IFN-alpha/beta on functions of different T cell populations.
    Klimpel GR; Infante AJ; Patterson J; Hess CB; Asuncion M
    Cell Immunol; 1990 Jul; 128(2):603-18. PubMed ID: 2162739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural killing activity and interferon production in multiple sclerosis.
    Zander H; Abb J; Kaudewitz P; Riethmüller G
    Lancet; 1982 Jan; 1(8266):280. PubMed ID: 6173558
    [No Abstract]   [Full Text] [Related]  

  • 25. [Role of immunoregulatory cells and natural killers in the pathogenesis of multiple sclerosis].
    Tunkel' OI; Saidov MZ; Cheredeev AN; Koval'chuk LV; Skriabina EG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(6):880-5. PubMed ID: 6224384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T cell lymphoid aggregates in idiopathic hypereosinophilic syndrome.
    Slater D
    J Clin Pathol; 1994 Mar; 47(3):287. PubMed ID: 8163709
    [No Abstract]   [Full Text] [Related]  

  • 27. [Interferon-producing and cytotoxic activity of natural killer cells in multiple sclerosis patients].
    Sorokin AM; Koval'chuk LV; Tunkel' OI; Cheknev SB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1987; 87(2):211-5. PubMed ID: 2437743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic alpha-interferon in multiple sclerosis. Long-term patient follow-up.
    Panitch HS
    Arch Neurol; 1987 Jan; 44(1):61-3. PubMed ID: 3800723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measurement of binding anti-IFNbeta antibodies in IFNbeta-treated MS patients: lessons for the clinician and basic scientist.
    Pachner AR
    J Neuroimmunol; 2008 Feb; 194(1-2):5-6. PubMed ID: 18031830
    [No Abstract]   [Full Text] [Related]  

  • 30. HLA typing and T-cell subpopulations in multiple sclerosis.
    Zaffaroni M; Di Falco M; Ghezzi A; Rizzolo L; Veneroni G; Marforio S
    J Neurol Neurosurg Psychiatry; 1988 Nov; 51(11):1465. PubMed ID: 2976813
    [No Abstract]   [Full Text] [Related]  

  • 31. Lack of correlation between impaired interferon production and natural killer activity of lymphocytes in multiple sclerosis.
    Stöger I; Tálas M; Benczúr M; Gyódi E; Petrányi GG; Pálffy G; Kotsy B
    Arch Virol; 1982; 71(3):259-65. PubMed ID: 6179500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-phospholipid antibodies and other immunological causes of recurrent foetal loss--a review of literature of various therapeutic protocols.
    Shetty S; Ghosh K
    Am J Reprod Immunol; 2009 Jul; 62(1):9-24. PubMed ID: 19527228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid interferon.
    Kastrukoff LF; Morgan NG; Aziz TM; Zecchini D; Berkowitz J; Paty DW
    J Neuroimmunol; 1988 Nov; 20(1):15-23. PubMed ID: 3183034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The interrelation of the expression of HLA class I and II proteins and of the costimulatory proteins CD11a/CD18 and CD16 with the lytic activity of resting and activated natural killer lymphocytes].
    Musatov MI; Petrova ED; Konenkov VI
    Tsitologiia; 1997; 39(7):617-28. PubMed ID: 9490502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Divergent effects of type-I interferons on regulatory T cells.
    Piconese S; Pacella I; Timperi E; Barnaba V
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):133-41. PubMed ID: 25466634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The eosinophil: doctor Jekyll or mister Hyde?].
    Bletry O
    Med Trop (Mars); 1998; 58(4 Suppl):423-5. PubMed ID: 10410359
    [No Abstract]   [Full Text] [Related]  

  • 37. The neglected role of type I interferon in the T-cell response: implications for its clinical use.
    Belardelli F; Gresser I
    Immunol Today; 1996 Aug; 17(8):369-72. PubMed ID: 8783497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
    Karavodin LM; Golub SH
    Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunology of the acquired immunodeficiency syndrome.
    McLaughlin PW; Lauter CB
    Henry Ford Hosp Med J; 1984; 32(2):107-15. PubMed ID: 6096312
    [No Abstract]   [Full Text] [Related]  

  • 40. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis.
    Rieckmann P; Weber F; Günther A; Martin S; Bitsch A; Broocks A; Kitze B; Weber T; Börner T; Poser S
    J Neuroimmunol; 1996 Feb; 64(2):193-200. PubMed ID: 8632062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.